imetelstat for lr-mds: insights from the imerge trial
Published 6 months ago • 767 plays • Length 2:57Download video MP4
Download video MP3
Similar videos
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:25
imerge subgroup study: imetelstat in patients with lr-mds previously exposed to esas
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
16:42
management of treatment-naïve lr-mds
-
45:23
creating health literate information: how to get the message across
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
2:19
imetelstat for transfusion-dependent r/r mds
-
3:50
imetelstat efficacy is independent of molecular subtypes in r/r lr-mds
-
3:47
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
7:05
state-of-the-art treatment regimens for lr-mds
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:40
the role of imetelstat in the treatment of myelofibrosis and insights into the impactmf study